PAVM Quote, Financials, Valuation and Earnings

Electromed has a net margin of -1105.92% compared to PAVmed's net margin of 12.11%. PAVmed's return on equity of -- beat Electromed's return on equity of 15.91%.

PAVmed has a consensus price target of $9.00, signalling upside risk potential of 1396.26%. On the other hand Electromed has an analysts' consensus of $37.00 which suggests that it could grow by 67.35%. Given that PAVmed has higher upside potential than Electromed, analysts believe PAVmed is more attractive than Electromed.

PAVmed has a beta of 1.133, which suggesting that the stock is 13.28% more volatile than S&P 500. In comparison Electromed has a beta of 0.594, suggesting its less volatile than the S&P 500 by 40.575%.

PAVmed has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Electromed offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. PAVmed pays -- of its earnings as a dividend. Electromed pays out -- of its earnings as a dividend.

PAVmed quarterly revenues are $10K, which are smaller than Electromed quarterly revenues of $16.3M. PAVmed's net income of $1.4M is lower than Electromed's net income of $2M. Notably, PAVmed's price-to-earnings ratio is -- while Electromed's PE ratio is 29.48x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for PAVmed is 3.69x versus 3.32x for Electromed. Usually stocks with elevated PS ratios are considered overvalued.

IRIDEX has a net margin of -1105.92% compared to PAVmed's net margin of -16.69%. PAVmed's return on equity of -- beat IRIDEX's return on equity of -157.91%.

PAVmed has a consensus price target of $9.00, signalling upside risk potential of 1396.26%. On the other hand IRIDEX has an analysts' consensus of -- which suggests that it could grow by 135.29%. Given that PAVmed has higher upside potential than IRIDEX, analysts believe PAVmed is more attractive than IRIDEX.

PAVmed has a beta of 1.133, which suggesting that the stock is 13.28% more volatile than S&P 500. In comparison IRIDEX has a beta of 0.737, suggesting its less volatile than the S&P 500 by 26.316%.

PAVmed has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. IRIDEX offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. PAVmed pays -- of its earnings as a dividend. IRIDEX pays out -- of its earnings as a dividend.

PAVmed quarterly revenues are $10K, which are smaller than IRIDEX quarterly revenues of $11.6M. PAVmed's net income of $1.4M is higher than IRIDEX's net income of -$1.9M. Notably, PAVmed's price-to-earnings ratio is -- while IRIDEX's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for PAVmed is 3.69x versus 0.29x for IRIDEX. Usually stocks with elevated PS ratios are considered overvalued.

Myomo has a net margin of -1105.92% compared to PAVmed's net margin of -2.16%. PAVmed's return on equity of -- beat Myomo's return on equity of -48.64%.

PAVmed has a consensus price target of $9.00, signalling upside risk potential of 1396.26%. On the other hand Myomo has an analysts' consensus of $9.25 which suggests that it could grow by 108.33%. Given that PAVmed has higher upside potential than Myomo, analysts believe PAVmed is more attractive than Myomo.

PAVmed has a beta of 1.133, which suggesting that the stock is 13.28% more volatile than S&P 500. In comparison Myomo has a beta of 1.548, suggesting its more volatile than the S&P 500 by 54.752%.

PAVmed has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Myomo offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. PAVmed pays -- of its earnings as a dividend. Myomo pays out -- of its earnings as a dividend.

PAVmed quarterly revenues are $10K, which are smaller than Myomo quarterly revenues of $12.1M. PAVmed's net income of $1.4M is higher than Myomo's net income of -$260.1K. Notably, PAVmed's price-to-earnings ratio is -- while Myomo's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for PAVmed is 3.69x versus 5.15x for Myomo. Usually stocks with elevated PS ratios are considered overvalued.

Stereotaxis has a net margin of -1105.92% compared to PAVmed's net margin of -118.53%. PAVmed's return on equity of -- beat Stereotaxis's return on equity of -139.2%.

PAVmed has a consensus price target of $9.00, signalling upside risk potential of 1396.26%. On the other hand Stereotaxis has an analysts' consensus of $4.50 which suggests that it could grow by 181.25%. Given that PAVmed has higher upside potential than Stereotaxis, analysts believe PAVmed is more attractive than Stereotaxis.

PAVmed has a beta of 1.133, which suggesting that the stock is 13.28% more volatile than S&P 500. In comparison Stereotaxis has a beta of 1.602, suggesting its more volatile than the S&P 500 by 60.223%.

PAVmed has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Stereotaxis offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. PAVmed pays -- of its earnings as a dividend. Stereotaxis pays out -- of its earnings as a dividend.

PAVmed quarterly revenues are $10K, which are smaller than Stereotaxis quarterly revenues of $6.3M. PAVmed's net income of $1.4M is higher than Stereotaxis's net income of -$7.5M. Notably, PAVmed's price-to-earnings ratio is -- while Stereotaxis's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for PAVmed is 3.69x versus 5.06x for Stereotaxis. Usually stocks with elevated PS ratios are considered overvalued.